[MUSIC] It is my pleasure to join Sujal Deshmuk,
who's a member of the staff at Novartis, and that he's going to share with us some
of his insights in his work at Novartis. So, Sujal,
would you please introduce yourself, and we'll roll right into the questions. >> Speaker 2: Hi,
my name is Sujal Deshmukh. I am part of the NIBR
division within Novartis, I work for the PKS group,
and within that I am leading the in vitro ADME efforts for
the PK science department. >> Speaker 1: Fantastic,
and PKS stands for? >> Pharmacokinetic sciences. >> Speaker 1: Pharmacokinetic sciences,
thank you very much. So, how did you get to your
current position at NIBR? >> Speaker 2: So,
my journey has been as part of the labs, that's where I started after my PhD. And I worked for quite a few years in
doing basic research within the labs, getting an understanding of the different
elements from a lab standpoint. Then I thought I would like to
try something a little different, which is to manage a lab and
to work with people, and so
I moved to Novartis with that intention. And for the last several years,
I've essentially been managing a lab within Novartis, and I've had now
changing levels of responsibility, initially it was a local Cambridge-based
role, which then became a global role. We've now started to take on
early discovery all the way into development as part of my responsibility. So it's been several years up to the point
that I have now what I am doing right now. >> Speaker 1: Can you share some details
about your educational background and what academic talents you had coming
into the pharmaceutical industry? >> Speaker 2: Sure, so I started my
main foray into this space when I did my Bachelor's in
Pharmaceutical Sciences, or as it was called, Bachelor's in Pharmacy. At that time, it was a four year
degree course where we learned all the different elements
of essentially making drugs. And that's when I got interested in the
different aspects of drug discovery and development, specifically,
what piqued my interest was pharmacology. And I decided to pursue that as
part of my future education, which is how I came to the United States, where I was accepted into
a pharmacology program. That's when I got introduced to
the amazing world of pharmacokinetics. So I initially joined in
a master's program, and then eventually, I converted that and
graduated with a PhD. And that is how my journey into my
educational background with pharmacology, pharmacokinetics. And then I worked with this very amazing
organ, which is the human placenta. And that's how I got interested about
the different elements that come with metabolism because I was investigating
the role of the human placenta for metabolizing drugs but also for transporting them across
the maternal fetal barrier. And so that really got me very much
interested in exploring this space of pharmacokinetics. >> Speaker 1: That's fascinating. When I think of metabolism, I tend to
think of the liver as the powerhouse for that, but metabolism occurs in a lot
of different tissues and organs. That's fantastic, thanks for sharing that. So, in your typical week or
typical day, are there some routine activities that you will typically
engage with in your line of work? >> Speaker 2: So
lots of meetings and more meetings. So now, in my role, I am, as I mentioned, managing a group of scientists
who are doing most of the work. I manage to work with them,
talk through them about the scientific challenges but
also anything that we run into as issues, I manage expectations,
I clarify roles and responsibilities. So what I'm really trying to do mostly
is to engage with the people within the group, but then also reach out to
people across different line functions. Ensure that we have alignment in terms
of the request, the expectations, the outputs that the department is having,
in terms of the science that we do, the results,
they're coming out in a timely manner. So that's pretty much most of my
day-to-day activities that I engage in. >> Speaker 1: So these meetings,
within pharmacokinetics, I'd imagine you are working with
multiple different programs at a time. How many programs would you guess
you support within your group? >> Speaker 2: So, the way we are
structured here is quite unique in a way that we support all
the different modalities, all the different therapeutic areas. So we are not tied to just specific
projects that we are assigned to. So we would handle anything that comes
through the pipeline that we would provide support for. So there are a lot of projects,
as you can imagine at Novartis, that we are supporting. So I am not specifically linked to
a particular project in my role, and then there are individuals who
work on specific projects, but from my standpoint,
I'm essentially managing, I would say, the entire discovery and
development portfolio. >> Speaker 1: And so the Cambridge site,
that is the main site for pharmacokinetic studies? >> Speaker 2: So both we have a presence
at Basel as well as in Cambridge, and so we work as a global team
to support any kind of request from an in vitro ADME standpoint as well. >> Speaker 1: As you explore
these different modalities, do you find that you have to work
more closely with formulation? Is there more interdependence
between people in those projects or is formulation,
are you extensions of one another? But I think formulation is
vitally important sometimes. >> Yes, so formulation is one of
the groups that we work very closely with, in addition to some other key partners,
which is our chemistry, right? So we have a lot of
touch points with them. Formulation would come as the next
stage when the molecule starts to look interesting. So because we provide kind of
the design part of it, but then also the characterization part of it. So formulation comes in and in that space
also we are early into the process, but also later into the clinic, right? So what impact it has,
because at that stage, we don't have all of this figured out,
but what we do know is the solubility, what we do know is the permeability. So there is some basic information
that we do have that we can offer, but we are also trying to think now,
creative, as I mentioned, with the complex modalities,
it's not just passive permeability. There are other mechanisms and just understanding that we get into a lot
of neural transporter space, even for oral absorption, even biologics,
it's not oral, it's subcutaneous. So what's happening there? So there is a lot of touch points with
formulation, especially when it comes to non oral deliveries as well with local
administration and things like that. So quite a lot of interaction just
to understand, as I mentioned, expectations, what can we deliver when
our model says something, don't overly interpret that it may not be for that
purpose that you think you are using it. So just educating each other on our needs. There's a lot of modeling that
happens in both spaces, and we just have to be how and
what can be used, how our data can essentially be feed
into what they are looking for. So, yeah,
we took quite a bit of interaction. >> Speaker 1: You mentioned diffusion,
there was a talk, there's an American chemical society,
it was an online symposium talk, and I couldn't get in because I think it was a
huge hit and everybody wanted to watch it. But it was about the fallacy of
passive diffusion in oral drugs, and it seemed a lot of strong statements
were going to be made in this. And you kind of referred to that a little
bit, everything's not passive diffusion, even in small molecules. So how important is passive diffusion? Is it still a driver, or
is it sometimes not that important? >> Speaker 2: I think it depends, right, it depends on what we understand
about that chemical matter. I wouldn't dismiss it
as not being important, because as much as I talk
about different modalities, there is still that very drug like space,
okay? Where we know we're going to get oral
exposure, we're going to have elimination driven through our classical
hepatic sips and things like that. But then occasionally, we do come across
a target that just cannot handle a normal chemical space, right, or
so called drug like space. And we do have to have creative chemistry,
and in that case, there are other things
that could be at play. So we do run into these. Do we have a very good
understanding of that? I would say, as I mentioned,
we are learning about these, but it's not that it's generally
applicable to every molecule or passive diffusion, is not the driver. I would say in most cases,
in the kind of space that we tend to work, where oral absorption is
a critical component, it's just by natural selection
you're going to get to that space, because otherwise you'll just see
the drug just doesn't make it in. And then you have to optimize it,
you have to dial in those properties, and then, yeah, passive diffusion
is an important component, and that's why we have assays that screen for
it very early on. But then we also learn that
where we see disconnects, and then we ask ourselves,
what's going on here? Maybe there is something
more to the story. So it's an evolving learning science,
which space, what kind of properties, what comes in? But as I said, it's pretty much
what we see as the big player. >> Speaker 1: Okay, great, thank you. So we've sort of talked about how your
position supports other scientists. So you manage your team, can you talk a little bit about what you
provide to teams outside your group? I think you've touched upon this a bit,
but could you elaborate a bit more? >> Speaker 2: Yes, so in my role, I am really trying to
facilitate these interactions. So when we talk about collaboration or
working with teams outside, as you said, within my group,
just ensuring these touch points, having a good understanding
of what they are looking for. What do we offer, any limitations that we
may have that they think we could provide that we may not, that's essentially
where I'm trying to involve and engage. On a scientific standpoint also, there is
the intricate science that we are doing. If there are concepts or
ideas that people have, how can we kind of leverage
that from their standpoint, but also then bring that to their attention or
how we are providing this. So there's a lot of these kind of
scientific exchanges that we have with other groups, most of this is all about
making the connections, the networking. We within our labs have certain
technologies that we have, and that's an expertise we can offer,
but then what's out there? What are some of the other things that
other groups may have come up with? So just understanding that is
also an important element. So just building that connectivity,
those networking opportunities, that's most of the outreach that we do. >> Speaker 1: Sounds like there's quite
a bit of knowledge base building to share with different teams as
they encounter problems. >> Speaker 2: Absolutely. >> Speaker 1: Can you talk about why you
made the conscious decision to work for a larger pharmaceutical company rather
than perhaps a smaller company? >> Speaker 2: So
it wasn't really by intention at the time. When you are graduating, you have
an idea of what you are looking for, and for me, it was quite clear that I
would be going to the industry. And so at that point, I was applying
to a few companies that I knew, and that's how I got my first
opportunity with a big pharma. And I like the culture,
I like the way we have an opportunity to impact
human health care. And so I just continued my journey there, not that a different setup would
not be desirable at this point, but it's just something that I thought
I could definitely continue and opportunities just kept coming. So from my first job,
I moved on to Novartis, and again, as you see, I like it here and
I definitely enjoy doing what I do. >> Speaker 1: That's great. Now, this next question is
really fairly specific, and maybe you're in your position,
you manage many projects, but can you talk a little bit
specifically about your current work? Maybe a specific project or maybe a
specific project that you facilitated and was particularly satisfying to you. And maybe the impact
that work had on patients who ultimately will
receive the medication. >> Speaker 2: So I sit a bit early in
the whole process of drug discovery and development. And as you probably know and
imagine, it takes several years before what we touch on can
actually make it into the clinic. But just knowing that what we are doing
is eventually going to impact human life, I think that in itself is
a very satisfying feeling. So, Novartis works on
multiple indications, ranging from oncology,
ophthalmology, cardiovascular. So, as I mentioned, we touch all of these. What we have been working on, and this is
something that I experience at Novartis, is the diversity of our portfolio. So we tend to refer these more
synthetic drugs, or small molecule, low molecule, as you referred to, but
then also the large molecules and the peptides, and now we hear about
these cell and gene therapies. So the breadth that we get to see and
experience and what we can contribute in
some of these novel chemical space is a constant learning experience. And it's, in a way, also unknown
territories that we get to explore. And that's really a very,
very interesting feeling, is to be the first in that, to kind
of learn something new in that area. So that's something that really is
extremely gratifying when it comes to really transforming human life in a
very different way that has not been done before. So that, I would say, is something
I really feel passionate about. >> Speaker 1: That's great. You touched upon this, but can you talk
about what you see as some of the big challenges, maybe in the field of
pharmacokinetics that are looming on the horizon that we'll
need to solve and figure out? >> Speaker 2: So from a pharmacokinetic
standpoint, what we provide from the early part all the way into
clinic is these translational or predictive abilities for our models or
our systems that we use. And we are seeing that our chemical
space is getting, as I mentioned, very diverse, our modalities are getting
more and more what we call complex. And so keeping up with that in terms of
the science as it is evolving in real-time and making these predictions and
coming up with these translational models that can be used for decision making,
that's a challenge in real-time. And so we are doing our best
to keep up with it, but we also understand there are limitations. We may not be ready today
to provide answers for the kind of questions we are getting,
either from a dose standpoint, so the pharmacokinetic aspect or
the exposure aspect. So we are also providing
insights into drug interactions. So what does our drug have an impact or
some other drug? And these are questions which require
a very good mechanistic understanding of the compound,
its disposition in the body. And we are, as I said,
as much as expertise the field has, it's a learning process right now, as I
mentioned, with the complex modalities. So that's a challenge, and we are,
as I said, working towards making our models a lot more translatable
and predictive as much as we can. >> Speaker 1: Fantastic. Sujal, thank you so much for
sharing your time and being available for this interview and sharing your experience
with the participants in this course. >> Speaker 2: Great,
thank you for having me. >> Speaker 1: Yeah,
absolutely, my pleasure. Take care. >> Speaker 2: Thank you.